National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings, 24322-24323 [2018-11213]
Download as PDF
<![CDATA[
24322
Federal Register / Vol. 83, No. 102 / Friday, May 25, 2018 / Notices
further develop, evaluate or
commercialize Epstein-Barr monoclonal
antibody technologies. For collaboration
opportunities, please contact Dr. Amy
Petrik, 240–627–3721; amy.petrik@
nih.gov.
Dated: May 10, 2018.
Suzanne M. Frisbie
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2018–11256 Filed 5–24–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Amy Petrik, Ph.D., 240–627–3721;
amy.petrik@nih.gov. Licensing
information and copies of the U.S.
patent applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
Middle East Respiratory Syndrome
Coronavirus Antibodies
amozie on DSK3GDR082PROD with NOTICES1
Description of Technology
Middle East Respiratory Syndrome
coronavirus (MERS-CoV) causes a
highly lethal pulmonary infection with
∼35% mortality. Currently there are no
prophylactic measures or effective
therapies. Inventors at the Vaccine
Research Center of the National Institute
of Allergy and Infectious Diseases have
identified and developed neutralizing
VerDate Sep<11>2014
18:28 May 24, 2018
Jkt 241001
monoclonal antibodies (nMAbs) against
the MERS-CoV. This invention
describes antibodies that target the
Spike (S) glycoprotein on the
coronavirus surface, which mediates
viral entry into host cells. These novel
antibodies target different regions of the
S protein, and when administered in
combination, reduce the possibility of
viral escape. In preclinical testing, these
nMAbs have demonstrated potent
protective effects, preventing death,
viral replication in the lower airways
and severe disease in challenge studies
with mice. In addition, these nMAbs
have potential application for use in
assays for detecting MERS-CoV S
protein in infected patients or animals.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications
Monoclonal antibodies developed
against multiple regions of the
coronavirus spike protein have potential
application in the prevention and
treatment of MERS-CoV. There is also
potential application for their use as a
diagnostic tool of infection.
Competitive Advantages
• In vitro models, the combinations of
antibodies have been demonstrated to
be effective in reducing viral escape.
• In vivo data in animal models
demonstrated a potent ability to control
infection.
• Applicable in diagnostic assays.
Development Stage
• In vivo data available (animal)
Inventors: Barney Graham (NIAID),
Wing-Pui Kong (NIAID), Kayvon
Modjarrad (NIAID), Lingshu Wang
(NIAID), Wei Shi (NIAID), Michael
Gordon Joyce (NIAID), Masaru Kanekiyo
(NIAID), John Mascola (NIAID).
Intellectual Property: HHS Reference
No. E–239–2014, U.S. Provisional Patent
Application Number 62/120,353 filed
February 25, 2015, PCT Patent
Application PCT/US2016/019395 filed
February 24, 2016, Europe Patent
Application Number 16711059.2 filed
February 24, 2016, South Korea Patent
Application Number 10–2017–7027105
filed September 25, 2017, Saudi Arabia
Patent Application Number 5173382168
filed August 21, 2017, and U.S. Patent
Application Number 15/553,466 filed
August 24, 2017.
Licensing Contact: Amy Petrik Ph.D.,
240–627–3721; amy.petrik@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize MERS-CoV monoclonal
antibodies. For collaboration
opportunities, please contact Amy
Petrik, Ph.D., 240–627–3721;
amy.petrik@nih.gov.
Dated: May 14, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2018–11255 Filed 5–24–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Eye Institute; Amended Notice
of Meeting
Notice is hereby given of a change in
the meeting of the National Advisory
Eye Council, June 14, 2018, 08:30 a.m.
to June 14, 2018, 05:00 p.m., NIH,
National Eye Institute, 5635 Fishers
Lane, Terrace Level Conference Rooms,
Rockville, MD 20852 which was
published in the Federal Register on
May 04, 2018, 83 FR 19791.
This meeting is being amended to
change the Open and Close times. The
Closed portion is now from 8:30 a.m. to
10:30 a.m. The Open portion is now
from 10:45 a.m. to 3:00 p.m. The
meeting is partially Closed to the public.
Dated: May 21, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–11211 Filed 5–24–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
E:\FR\FM\25MYN1.SGM
25MYN1
24323
Federal Register / Vol. 83, No. 102 / Friday, May 25, 2018 / Notices
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01).
Date: June 15, 2018.
Time: 1:30 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Priti Mehrotra, Ph.D.,
Chief, Immunology Review Branch Scientific
Review Program, Division of Extramural
Activities, Room #3G40, National Institutes
of Health/NIAID, 5601 Fishers Lane, MSC
9823, Bethesda, MD 20892–7616, 240–669–
5066, pmehrotra@niaid.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Planning Grant (R34); NIAID Clinical Trial
Implementation Grant (R01); NIAID Clinical
Trial Implementation Cooperative Agreement
(U01).
Date: June 18–19, 2018.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Maryam Feili-Hariri,
Ph.D., Scientific Review Officer Scientific
Review Program Division of Extramural
Activities, National Institutes of Health/
NIAID, 5601 Fishers Lane, Rockville, MD
20852, 240–669–5026, haririmf@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: May 21, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–11213 Filed 5–24–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
amozie on DSK3GDR082PROD with NOTICES1
U.S. Customs and Border Protection
Approval of Omni Hydrocarbon
Measurement, Inc. (Crosby, TX), as a
Commercial Gauger
U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION: Notice of approval of Omni
Hydrocarbon Measurement, Inc., as a
commercial gauger.
AGENCY:
VerDate Sep<11>2014
19:10 May 24, 2018
Jkt 241001
SUMMARY: Notice is hereby given,
pursuant to CBP regulations, that Omni
Hydrocarbon Measurement, Inc. has
been approved to gauge petroleum and
certain petroleum products for customs
purposes for the next three years as of
July 6, 2017.
Applicable Dates: The approval of
Omni Hydrocarbon Measurement, Inc.,
as commercial gauger became effective
on July 6, 2017. The next triennial
inspection date will be scheduled for
July 2020.
FOR FURTHER INFORMATION CONTACT:
Melanie Glass, Laboratories and
Scientific Services, U.S. Customs and
Border Protection, 1331 Pennsylvania
Avenue NW, Suite 1500N, Washington,
DC 20229, tel. 202–344–1060.
Notice is
hereby given pursuant to 19 CFR 151.13,
that Omni Hydrocarbon Measurement,
Inc., 914 Kennings Avenue, Crosby, TX
77532, has been approved to gauge
petroleum and certain petroleum
products for customs purposes, in
accordance with the provisions of 19
CFR 151.13. Omni Hydrocarbon
Measurement, Inc. is approved for the
following gauging procedures for
petroleum and certain petroleum
products per the American Petroleum
Institute (API) Measurement Standards:
SUPPLEMENTARY INFORMATION:
API chapters
8 ...................
Title
Sampling.
Anyone wishing to employ this entity
to conduct gauger services should
request and receive written assurances
from the entity that it is approved by the
U.S. Customs and Border Protection to
conduct the specific test or gauger
service requested. Alternatively,
inquiries regarding the specific test or
gauger service this entity is approved to
perform may be directed to the U.S.
Customs and Border Protection by
calling (202) 344–1060. The inquiry may
also be sent to cbp.labhq@dhs.gov.
Please reference the website listed
below for a complete listing of CBP
approved gaugers and accredited
laboratories. https://www.cbp.gov/sites/
default/files/documents/gaulist_3.pdf.
Dated: May 1, 2018.
Dave Fluty,
Executive Director, Laboratories and
Scientific Services, Operations Support.
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Accreditation and Approval of
Inspectorate America Corporation
(Houston, TX), as a Commercial
Gauger and Laboratory
U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION: Notice of accreditation and
approval of Inspectorate America
Corporation (Houston, TX), as a
commercial gauger and laboratory.
AGENCY:
SUMMARY: Notice is hereby given,
pursuant to CBP regulations, that
Inspectorate America Corporation
(Houston, TX), has been approved to
gauge petroleum and certain petroleum
products and accredited to test
petroleum and certain petroleum
products for customs purposes for the
next three years as of July 11, 2017.
DATES: Inspectorate America
Corporation (Houston, TX) was
accredited and approved, as a
commercial gauger and laboratory as of
July 11, 2017. The next triennial
inspection date will be scheduled for
July 2020.
FOR FURTHER INFORMATION CONTACT: Dr.
Justin Shey, Laboratories and Scientific
Services Directorate, U.S. Customs and
Border Protection, 1300 Pennsylvania
Avenue NW, Suite 1500N, Washington,
DC 20229, tel. 202–344–1060.
SUPPLEMENTARY INFORMATION: Notice is
hereby given pursuant to 19 CFR 151.12
and 19 CFR 151.13, that Inspectorate
America Corporation, 16025–C
Jacintoport Blvd., Houston, TX 77015
has been approved to gauge petroleum
and certain petroleum products and
accredited to test petroleum and certain
petroleum products for customs
purposes, in accordance with the
provisions of 19 CFR 151.12 and 19 CFR
151.13. Inspectorate America
Corporation is approved for the
following gauging procedures for
petroleum and certain petroleum
products from the American Petroleum
Institute (API):
API
chapters
3 ...................
7 ...................
8 ...................
12 .................
17 .................
Title
Tank Gauging.
Temperature Determination.
Sampling.
Calculations.
Marine Measurement.
[FR Doc. 2018–11312 Filed 5–24–18; 8:45 am]
Inspectorate America Corporation is
accredited for the following laboratory
analysis procedures and methods for
BILLING CODE 9111–14–P
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
E:\FR\FM\25MYN1.SGM
25MYN1
]]>Agencies
[Federal Register Volume 83, Number 102 (Friday, May 25, 2018)]
[Notices]
[Pages 24322-24323]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-11213]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material,
[[Page 24323]]
and personal information concerning individuals associated with the
grant applications, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01).
Date: June 15, 2018.
Time: 1:30 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Priti Mehrotra, Ph.D., Chief, Immunology Review
Branch Scientific Review Program, Division of Extramural Activities,
Room #3G40, National Institutes of Health/NIAID, 5601 Fishers Lane,
MSC 9823, Bethesda, MD 20892-7616, 240-669-5066,
[email protected].
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; NIAID Clinical Trial Planning Grant
(R34); NIAID Clinical Trial Implementation Grant (R01); NIAID
Clinical Trial Implementation Cooperative Agreement (U01).
Date: June 18-19, 2018.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Maryam Feili-Hariri, Ph.D., Scientific Review
Officer Scientific Review Program Division of Extramural Activities,
National Institutes of Health/NIAID, 5601 Fishers Lane, Rockville,
MD 20852, 240-669-5026, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: May 21, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-11213 Filed 5-24-18; 8:45 am]
BILLING CODE 4140-01-P
